Adma Biologics reported $191.64M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Adma Biologics USD 191.64M 1.2M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Novavax USD 246.3M 200K Dec/2025
Omeros USD 403.72M 27.2M Jun/2024
Takeda JPY 4.17T 245.32B Sep/2026